with renal insufficiency and may increase from 1.5 to Methods. Hirudin anticoagulation was performed in seven 50 hours in anuric patients [4] . Published experience in critically ill patients with suspected HIT. Four patients were dialysis patients is limited. Preliminary studies showed initially anuric. Three patients had residual renal function. In intermittent hemodialysis with hirudin to be possible all 64 CVVHD treatments (mean duration 12 hr), a polysulfone high-flux hemodialyzer (0.75 m 2 ) with a dialysate flow rate of without major side effects [5, 6] . In these early studies, 1 .5 liter/hr and an ultrafiltration rate of up to 200 ml/hr was hirudin was given for one single dialysis session only. In used. Hirudin was given either as continuous intravenous infuone patient, hirudin was used for more than 50 consecusion or as repetitive intravenous boli. Monitoring of anticoagutive dialysis sessions without adverse effects [7] . lation was performed by measurements of the systemic activated partial thromboplastin time (aPTT).
Given the prolonged half-life of hirudin in patients to one week. Thus, the use of hirudin in critically ill or repetitive intravenous boli (0.007 to 0.04 mg/kg, N ϭ 5) were given. Two patients required blood transfusions prior to patients with renal failure could markedly increase their and during hirudin treatment. In five patients without a high bleeding risk. A number of patients with proven or susbleeding risk, the hirudin dose was adjusted to achieve the pected HIT on intermittent hemodialysis were successtarget aPTT (1.5 to 2.0 ϫ baseline) in order to prevent thromfully treated with hirudin at our center. In these patients, hirudin dose has to be reduced because of renal failure, and may require adjustment for residual or recovering renal function and extracorporal elimination.
METHODS

Patients
Between January and December 1998, seven intensive Recombinant hirudin (lepirudin, Refludan) has been approved in both Europe and the United States for the care patients (4 males and 3 females; mean age 57 years, range 30 to 70) were suspected to have HIT while additionally requiring continuous hemodialysis because of Monitoring of anticoagulation was performed by refactor IV complexes (HPIA; Diagnostica Stago, distribpetitive measurements of the systemic activated partial uted by Roche Diagnostica, Basel, Switzerland). Basic thromboplastin time (aPTT) according to standard methpatient characteristics are given in Table 1 . All patients ods (analyzer, Behring Coagulation System; reagent, initially presented with systemic inflammatory response Pathromtin SL; both by Dade Behring, Liederbach, Gersyndrome, which could be defined as sepsis caused by many). documented infection in five patients. All patients suffered from multiple-organ dysfunction syndrome. At the Hemodialysis procedure initiation of hirudin treatment, four patients were anuric, Continuous venovenous hemodialysis was performed and three patients had residual diuresis (800 to 3800 ml/ with a polysulfone high-flux hemodialyzer (AV400, 0.75 day; Table 2) . m 2 ; Fresenius, Bad Homburg, Germany) using a Fresenius ADM08 dialysis machine (Fresenius) with a bicarHirudin anticoagulation bonate dialysate at a flow rate of 1.5 liter/hr. The blood On suspicion of HIT, anticoagulation was changed flow was 100 ml/min. The ultrafiltration rate depended from unfractionated heparin (Heparin-Natrium Braun; on the patient's need (0 to 200 ml/hr). Braun, Melsungen, Germany) to recombinant hirudin (lepirudin, Refludan; Hoechst Marion Roussel, Bad So-RESULTS den, Germany). Because of the high risk of thrombosis Course of platelet counts in patients with HIT, hirudin was given intravenously. Anticoagulation strategy was targeted to protect the paAll patients had developed severe thrombocytopenia tient from clot formation without inappropriately induring heparin treatment. The mean platelet counts fell creasing the bleeding risk. Hirudin was applied either as from 202 Ϯ 26/nl to 39 Ϯ 3/nl (Fig. 1) . The earliest continuous intravenous infusion or as repetitive intravedrop in platelet count was observed on day 3 of heparin treatment. After changing anticoagulation to recombinous boli. nant hirudin, platelet counts recovered within five to was switched from intravenous boli to intravenous infuseven days (Fig. 1) .
sion after the recovery of renal function and the termination of continuous hemodialysis treatment (data not Continuous hemodialysis shown). Continuous venovenous hemodialysis had to be initiAdverse reactions ated because of acute renal failure. Upon anticoagulation with hirudin, a total of 64 CVVHD treatments was perNo patient developed allergic reactions on hirudin apformed with an overall duration of 785 hours (Table 2) .
plication. Overt bleeding was not observed. Despite this, The mean duration of individual continuous hemodialytwo patients (patient 1 and patient 2) required blood sis treatment was 12 hours, with a range of 3 to 30 hours. transfusion prior to and during hirudin treatment. The transfusion requirement did not increase upon changing Hirudin anticoagulation anticoagulation to hirudin. Anticoagulation with recombinant hirudin had to be Patients' outcome individualized according to the risk of bleeding or thrombosis. In addition, hirudin dose requirements depended Two patients died. One patient (patient 6) suffered on residual renal function and extracorporal clearance. from repeated acute myocardial infarction. The other In five patients, hirudin was applied as repetitive intrapatient (patient 3) showed severe refractory vasculitis. venous boli. In three anuric patients, the respective dose Both died of prolonged cardiogenic shock. Fatal outper single intravenous bolus ranged from 0.007 to 0.025 come in both patients was not related to hirudin anticomg/kg body wt, corresponding to a mean daily dose of agulation. The five survivors showed no thromboembolic 0.013 to 0.054 mg/kg body wt ( Table 3 ). The mean aPTT events after starting hirudin. They recovered from multireached by this regimen was 44 to 48 seconds (aPTT ple organ dysfunction syndrome. Two initially anuric ratio 1.3 to 1.7). In two polyuric patients, the dose of patients (patients 1 and 2) and all three polyuric patients intravenous boli ranged from 0.013 to 0.04 mg/kg body (patients 4, 5 and 7) eventually recovered renal function. wt, corresponding to a mean daily dose of 0.08 mg/kg Further hemodialysis treatment was not necessary after body wt in both patients. The mean aPTT in these padischarge from the hospital. tients was 45 and 53 seconds (aPTT ratio 1.3 and 1.6), respectively (Table 3) . DISCUSSION In two patients, hirudin was applied as continuous Heparin-induced thrombocytopenia type II is a severe intravenous infusion. In one anuric patient (patient 6), complication of heparin anticoagulation, which in spite anticoagulation was aimed to markedly reduce the high of low platelet counts often leads to potentially liferisk of thrombosis. The respective dose was 0.006 to threatening thromboembolic complications [1, 8] . Upon 0.009 mg/kg body wt/hr, resulting in a mean daily dose suspicion, immediate stop of heparin treatment and of 0.15 mg/kg body wt. With this regimen, the mean switch to a suitable alternative anticoagulant are mandaaPTT was 100 seconds (aPTT ratio 3.3). Overt bleeding tory [1] , which in Europe is increasingly performed with was not observed, and blood transfusion was not rerecombinant hirudin. In patients with renal failure required. The other patient was polyuric (patient 7). Antiquiring continuous dialysis, uncertainty exists regarding coagulation was performed with an intravenous infusion the safe use of hirudin. In our study of critically ill paof hirudin in a dose of 0.013 to 0.025 mg/kg body wt/hr tients with acute renal failure who were suspected of (mean daily dose 0.5 mg/kg body wt). In this patient, the having developed HIT, anticoagulation was performed mean aPTT was 62 seconds (aPTT ratio 1.5; Table 3 ).
In two patients (patients 2 and 4), hirudin application with recombinant hirudin to prevent white clot forma-
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tion sufficiently. Low doses of hirudin were applied to treatment. To minimize bleeding, a mean daily hirudin dose of only 0.013 mg/kg body wt was given in bolus avoid bleeding complications.
form, which resulted in a mean aPTT of 45 seconds Laboratory monitoring of hirudin treatment (aPTT ratio 1.3; Table 3 ). The transfusion requirement did not increase after switch of anticoagulation to hiruIn HIT patients, hirudin is given to avoid clot formation, but at the same time the risk of bleeding has to be din. In case of hirudin overdosage, the rapid elimination of the drug may be required, which could be performed minimized. The ideal laboratory monitoring parameter should reliably guide anticoagulation between the risk by high-volume hemofiltration using high-flux hemodialyzers [13] . Compared with hemofiltration, hemodialysis of bleeding and clotting. aPTT has frequently been used to monitor hirudin treatment [9] . However, its adequacy provides lower hirudin elimination, as the high molecular weight of hirudin impairs diffusion. Thus, if patients are for monitoring hirudin anticoagulation has been debated because a correlation with hirudin levels is not linear at treated with hemofiltration, a higher dosage of hirudin may be required than that used in our study. higher hirudin concentrations [10, 11] . Up to a hirudin plasma concentration of 0.5 g/ml, aPTT was found to Use of hirudin in patients with a high clotting risk be prolonged linearly in a dose-dependent manner [11] . Above that concentration, a nonlinear relationship beIn our study, one patient suffering from severe coronary artery disease repeatedly developed thromboemtween hirudin plasma levels and respective aPTT prolongation was observed, resulting in a smaller extent of bolic complications during the prehirudin period (patient 6). Hirudin anticoagulation was thus aimed to reach a aPTT prolongation at higher hirudin concentrations [10, 11] . aPTT appears to be a useful monitoring parameter, high aPTT ratio despite anuria. To avoid clotting, a mean daily dose of 0.15 mg/kg body wt was applied as continuprovided that hirudin anticoagulation is performed in the low-dose range, as was done in this study. Clotting ous intravenous infusion, which resulted in a mean aPTT of 100 seconds (aPTT ratio 3.3). Overt bleeding was not tests based on thrombin time such as activated clotting time (ACT) are not helpful with regard to hirudin moniobserved, and blood transfusion was not required. When applying larger doses of hirudin in patients with renal toring because of their narrow linear dose-response curve [11] . A recently developed test, ecarin clotting time failure, the use of additional monitoring tests such as ECT or chromogenic assays for determination of hirudin (ECT) allows the anticoagulation effect to be monitored with an almost linear correlation to hirudin concentraplasma levels is recommended, because aPTT may no longer correlate with hirudin levels and bleeding risk. tions over the whole range from subtherapeutic to toxic hirudin levels (0.05 to 5.0 g/ml) [11] . The ECT assay is Increasing hirudin dose requirements with recovery of currently not commercially available, hindering its broad renal function use as a bedside test. Chromogenic assays for accurate determination of hirudin plasma levels are commercially Hirudin dosing depends on the volume of extracellular fluid and on drug elimination by residual renal function available in Europe but are not yet introduced in laboratory routine. Since completion of this study, a chromoand extracorporal elimination, and hirudin removal by nonrenal clearance pathways can be neglected. Its distrigenic assay for determination of hirudin concentrations (analyzer, Behring Coagulation System; reagent, Beribution volume may increase because of volume substitution often necessary in critically ill patients. Initially and chrom Hirudin; both by Dade Behring) has been established at our center. However, in a large prospective, for maintenance dosing, the same boli were used, guided by the aPTT response. Increasing renal clearance caused recently published multicenter study on hirudin treatment of HIT patients, hirudin plasma levels did not corby recovering renal function will contribute to necessary hirudin dose adjustments. When patient 2 was initially relate with bleeding complications [9] . This may be due in part to sustained antithrombotic activity of hirudin anuric, the mean daily hirudin dose to achieve an aPTT of 44 seconds (aPTT ratio 1.3) was 0.026 mg/kg body even after its plasma clearance, which is most likely based on its action on clot-bound thrombin [12] . Because even wt. Upon recovering renal function, dose requirements increased in correlation to increasing daily urine volume. an accurate test for measurement of hirudin plasma levels may not predict the bleeding risk, we attempted to A mean daily hirudin dose of 1 mg/kg body wt did not prolong aPTT during that period. keep aPTT levels between 1.5 and 2.0 ϫ baseline values. Moreover, repetitive evaluation of the clinical situation In summary, these first clinical data show that anticoagulation with hirudin in critically ill patients on continuis mandatory.
ous hemodialysis can be performed without excessive Use of hirudin in patients with a high bleeding risk bleeding risk by combining close clinical and laboratory monitoring. The hirudin dose has to be reduced because In our study, one patient suffering from alcoholic hepatitis, severe malnutrition, and viral pneumonia (patient of renal failure but requires adjustment for residual or recovering renal function and extracorporal elimination. 1) needed repetitive blood transfusions prior to hirudin
